Astria Therapeutics Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 59
- Market Cap
- -
- Website
- http://www.astriatx.com
- Introduction
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study of Navenibart in Participants With Hereditary Angioedema
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Astria Therapeutics, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT06842823
- Locations
- 🇺🇸
Site 9, Birmingham, Alabama, United States
🇺🇸Site 14, San Diego, California, United States
🇺🇸Site 11, Colorado Springs, Colorado, United States
A Study of STAR-0310 in Healthy Adult Participants
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Astria Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06782477
- Locations
- 🇺🇸
Austin Clinical Research Unit - Early Clinical Development, Austin, Texas, United States
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Astria Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06007677
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD, Scottsdale, Arizona, United States
🇺🇸Acuro Research, Little Rock, Arkansas, United States
A Study of STAR-0215 in Participants With Hereditary Angioedema
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Astria Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05695248
- Locations
- 🇺🇸
Acuro Research, Inc., Little Rock, Arkansas, United States
🇺🇸Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD., Scottsdale, Arizona, United States
A Study of STAR-0215 in Healthy Adult Participants
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: STAR-0215 (IV)Drug: STAR-0215 (SC)Drug: Placebo (IV)Drug: Placebo (SC)
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Astria Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05477160
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States